Celsion Corporation 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Celsion Corporation for the period ended December 31, 2000. The company is a clinical-stage biotechnology firm focused on developing thermotherapy systems for cancer and benign prostatic hyperplasia (BPH). As of the filing date, the company had no commercial product sales and was in Phase II clinical testing for its new equipment.
Key Financial Metrics
- Revenue: $0 (No product sales recorded for the quarter).
- Net Loss: $1,374,452 for the three months ended December 31, 2000.
- Operating Expenses: $1,486,975 (Selling, general, and administrative: $930,600; Research and development: $556,375).
- Cash and Cash Equivalents: $7,480,990 as of December 31, 2000.
- Working Capital: $7,306,759 surplus (Current Assets: $7,788,967; Current Liabilities: $482,208).
- Accumulated Deficit: $27,821,869.
- Debt: Notes payable of $114,778; no bank financing arrangements exist.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 65% to $1.37 million from $834,663 in the same period in 1999.
- Operating Expenses: Total operating expenses rose 77% to $1.49 million from $842,043.
- SG&A: Increased 191% to $930,600, driven by legal fees, marketing, and travel related to a withdrawn registration statement, plus office expansion costs.
- R&D: Increased 156% to $556,375, primarily due to engineering costs for BPH and breast cancer treatment equipment.
- Cash Flow: Net cash used in operating activities increased to $1.28 million from $1.18 million in the prior year quarter.
Outlook, Risks, and Management Commentary
- Guidance: Management expects to expend approximately $8 million for the full fiscal year 2001 on research, development, and administration. The company expects to meet these needs with current resources but anticipates continued operating losses.
- Capital Needs: The company has no committed sources of additional financing. Future funding will likely require equity or debt offerings, strategic alliances, or other sources. Failure to secure funding could force delays or scaling back of operations.
- Risks: Significant risks include the inability to obtain regulatory approvals, the slow development of the thermotherapy market, and the need for substantial additional capital. The company has a history of negative net worth and negative cash flows.
- Unusual Items: The company withdrew a Form S-1 registration statement in December 2000. Additionally, 115,567 shares of common stock were issued to consultants valued at $216,417.
Investor Verification Checklist
- Verify the status and timeline of Phase II clinical trials for breast cancer and BPH treatment systems.
- Confirm the sufficiency of the $7.48 million cash balance to fund the projected $8 million fiscal year 2001 budget.
- Review the details of the litigation against former director Warren C. Stearns regarding the rescission of warrants for 3.4 million shares.
- Monitor for any new equity or debt financing announcements given the lack of committed funding sources.
- Assess the impact of the withdrawn Form S-1 registration on future capital raising strategies.